Custom Search
News
Friday 12 January 2007
Advancis Sees 2006 Keflex Sales Below Prior View
Advancis Pharmaceutical Corp. on Friday lowered its revenue estimates from its Keflex antibiotic products for 2006, saying sales did not pick up as fast as the drugmaker expected.
The company now expects total revenue from sales of Keflex of about $5 million, lower than the prior expectations of $7 million to $10 million, it said in a statement.
"While our Keflex 750 product sales have continued to increase month-over-month, we did not experience the rapid sales uptake in late 2006 that we previously anticipated," Chief Executive Edward Rudnic said. Advancis said it gave significantly discounted Keflex 750 capsules to select pharmacies in the United States, to expand product availability beyond the initial launch distribution.
The company also said it had about $15 million of cash, cash equivalents and marketable securities at the end of 2006.